Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

The European Commission approved the combination of teclistamab and daratumumab for adult patients with relapsed or refractory multiple myeloma after at least one prior therapy, based on the phase 3 MajesTEC-3 trial demonstrating significant improvement in progression-free and overall survival compared to standard treatments.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Cancer therapy founders now face a defined regulatory pathway and earlier market access for immunotherapy combos in Europe. You need to position your clinical assets against teclistamab's success to avoid losing competitive edge.

◆ Coverage

1 source · 21 Aug 2026

◆ Related on Wire

◆ Topics

Biotechmultiple-myelomadrug-approvalimmunotherapyclinical-trialoncology